Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 216

Sort by

Sort Order Select

Journal Articles

Chemotherapy or Stem Cell Transplantation in Adult High Risk Ph/BCR::ABL1-Negative ALL Patients with Early MRD Negativity: Results of the Randomized GMALL Trial 08/2013

Blood (2024) 144 (Supplement 1): 961.

https://doi.org/10.1182/blood-2024-199060

Published: 2024

Journal Articles

The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients

Jan-Niklas Eckardt, Marius Bill, Konstanze Döhner, Christian Rausch, Klaus H Metzeler, Karsten Spiekermann, Sebastian Stasik, Tim Sauer, Sebastian Scholl, Andreas Hochhaus, Martina Crysandt, Tim H. H. Brummendorf, Utz Krug, Bernhard Wörmann, Hermann Einsele, Wolfgang Hiddemann, Dennis Görlich, Maria Cristina Sauerland, Björn Steffen, Andreas Neubauer, Andreas Burchert, Kerstin Schaefer-Eckart, Wolfgang E. Berdel, Christoph Schliemann, Stefan W. Krause, Mathias Hänel, Maher Hanoun, Martin Kaufmann, Lars Fransecky, Jan Braess, Johannes Schetelig, Jan Moritz Middeke, Lars Bullinger, Michael Heuser, Felicitas R Thol, Hubert Serve, Claudia D Baldus, Uwe Platzbecker, Carsten Mueller-Tidow, Barbora Weinbergerova, Jiri Mayer, Pierre-Yves Dumas, Sarah Bertoli, Eric Delabesse, Christian Récher, Arnaud Pigneux, Tobias Herold, Arnold Ganser, Hartmut Döhner, Martin Bornhäuser, Christian Thiede, Christoph Röllig

Blood (2024) 144 (Supplement 1): 2934.

https://doi.org/10.1182/blood-2024-201945

Published: 2024

Journal Articles

Characterizing the Microbiome-Immune Axis in Hematopoietic Stem Cell Recipients

Sabrina A. Becker, Julius C. Enssle, Anne C. Wilke, Sylvia Pfundt, Nico Zeltner, Ana Jankovic, Sebastian Wolf, Thomas A. Wichelhaus, Volkard A. J. Kempf, Maria J. G. T. Vehreschild, Hubert Serve, Thomas Oellerich, Björn Steffen, Sebastian Scheich

Blood (2024) 144 (Supplement 1): 2022.

https://doi.org/10.1182/blood-2024-207279

Published: 2024

Journal Articles

Outcome of Patients with Hematologic or Molecular Relapsed/Refractory (R/R) Acute T- Lymphoblastic Leukemia - Data from the GMALL Study Group

Anjali Cremer, Maher Hanoun, Ralph Wäsch, Simon Raffel, Klaus Wethmar, Andreas Viardot, Walter Fiedler, Knut Wendelin, Lore Marretta, Wolfram Jung, Roland Schroers, Vladan Vucinic, Monika Brüggemann, Stefan Schwartz, Hubert Serve, Nicola Goekbuget

Blood (2024) 144 (Supplement 1): 1436.

https://doi.org/10.1182/blood-2024-202270

Published: 2024

Journal Articles

10 Year Follow-up of CALGB 10603/Ratify: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years

Blood (2024) 144 (Supplement 1): 218.

https://doi.org/10.1182/blood-2024-201058

Published: 2024

Journal Articles

Age-Stratified Game-Theory-Informed Machine Learning of Molecular Alterations Unveils Prognostic Divergence in 3062 Pediatric and Adult Acute Myeloid Leukemia Patients

Blood (2024) 144 (Supplement 1): 2211.

https://doi.org/10.1182/blood-2024-198861

Published: 2024

Journal Articles

Clonal Dynamics of Leukemic and Clonal Hematopoiesis Mutations Predict Relapse in Single Cell MRD Analysis of AML in First Complete Remission

Blood (2024) 144 (Supplement 1): 4337.

https://doi.org/10.1182/blood-2024-209953

Published: 2024

Journal Articles

HLA-DR Expression on Leukemic Progenitor Cells before Allogeneic Hematopoietic Cell Transplantation Adds Prognostic Value in the Presence of MRD

Maximilian Alexander Rohnert, Jonas Schadt, Michael Kramer, Christoph Röllig, Johannes Schetelig, Friedrich Stölzel, Désirée Kunadt, Jan Moritz Middeke, Lars Thielecke, Friedemann Uschner, Ingmar Glauche, Christian Thiede, Martin Bornhaeuser, Uta Oelschlaegel, Malte von Bonin, Uwe Platzbecker, Claudia D Baldus, Hubert Serve, Carsten Mueller-Tidow

Blood (2024) 144 (Supplement 1): 2948.

https://doi.org/10.1182/blood-2024-194874

Published: 2024

Journal Articles

Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1 -Mutated AML - the SAL/AMLCG Vincent Trial

Blood (2024) 144 (Supplement 1): 1527.1.

https://doi.org/10.1182/blood-2024-198164

Published: 2024

Journal Articles

Follow-up of the Randomized ASAP Trial Shows No Survival Advantage for Patients with Poor Responsive or Relapsed AML Who Received Intensive Salvage Chemotherapy for Remission Induction Prior to Allogeneic Transplantation Compared to Immediate Allogeneic Transplantation

Blood (2024) 144 (Supplement 1): 776.

https://doi.org/10.1182/blood-2024-204763

Published: 2024

Journal Articles

Update on GMALL Trial 08/2013 Shows Durable Favorable Outcome of Newly Diagnosed Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) with Imatinib, Dose-Reduced Induction Followed By Stem Cell Transplantation

Heike Pfeifer, Fabian Lang, Walter Fiedler, Matthias Stelljes, Folker Schneller, Björn Steffen, Boris Böll, Andreas Viardot, Christoph Faul, Lino L. Teichmann, Hendrik Poeck, Joerg Westermann, Kerstin Schäfer-Eckart, Thomas Heinicke, Thomas Burmeister, Stefan Schwartz, Monika Brueggemann, Hubert Serve, Nicola Goekbuget

Blood (2024) 144 (Supplement 1): 840.

https://doi.org/10.1182/blood-2024-201217

Published: 2024

Journal Articles

Incidence, Risk Factors, and Outcomes of Candida Bloodstream Infections in Hematological and Oncological Patients

Sebastian Wolf, Sarah Weber, Aaron Janetta, Friederike Klein, Julius C. Enssle, Michael Hogardt, Volkard A. J. Kempf, Johanna Kessel, Maria J. G. T. Vehreschild, Björn Steffen, Thomas Oellerich, Hubert Serve, Sebastian Scheich

Blood (2024) 144 (Supplement 1): 2866.

https://doi.org/10.1182/blood-2024-205960

Published: 2024

Journal Articles

Epigenetic control over the cell-intrinsic immune response antagonizes self-renewal in acute myeloid leukemia

Blood (2024) 143 (22): 2284–2299.

https://doi.org/10.1182/blood.2023021640

Published: 2024

Includes: Supplemental data

Journal Articles

Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Patients with Ph/BCR::ABL Negative B-Precursor Adult Lymphoblastic Leukemia (ALL): Preliminary Results of the GMALL Bold Trial

Nicola Goekbuget, Stefan Schwartz, Christoph Faul, Max S. Topp, Marion Subklewe, Andrea Renzelmann, Andrea Stoltefuss, Bernd Hertenstein, Anne Wilke, Simon Raffel, Nadja Jäkel, Vladan Vucinic, Dirk Markus Niemann, Lena Reiser, Hubert Serve, Monika Brüggemann, Andreas Viardot

Blood (2023) 142 (Supplement 1): 964.

https://doi.org/10.1182/blood-2023-180472

Published: 2023

Journal Articles

Secondary-Type Mutations Do Not Impact the Favorable Outcome of NPM1 -Mutated Acute Myeloid Leukemia Patients - Results from a Large Cohort of Intensively Treated Patients

Blood (2023) 142 (Supplement 1): 721.

https://doi.org/10.1182/blood-2023-186160

Published: 2023

Journal Articles

CNS Irradiation in Adult De Novo B-Precursor ALL / Lbl: Results of the Randomized GMALL T rial 08/2013 Indicate Potential Antileukemic Efficacy

Blood (2023) 142 (Supplement 1): 828.

https://doi.org/10.1182/blood-2023-179442

Published: 2023

Journal Articles

Impact of KMT2A -PTD Mutational Subgroups on Outcome of AML Patients after Induction Therapy and Allogeneic Hematopoietic Cell Transplantation

Blood (2023) 142 (Supplement 1): 2236.

https://doi.org/10.1182/blood-2023-187273

Published: 2023

Journal Articles

Immune Responses after One Versus Two Influenza A/B Vaccinations in Patients with Multiple Myeloma

Julius Enssle, Tonio Brinkschmidt, Ralf Dürrwald, Sebastian Wolf, David Zurmeyer, Björn Steffen, Evelyn Ullrich, Hubert Serve, Thomas Oellerich, Ivana von Metzler

Blood (2023) 142 (Supplement 1): 4737.

https://doi.org/10.1182/blood-2023-180096

Published: 2023

Journal Articles

LSD1 Inhibition Synergizes with Venetoclax in Acute Myeloid Leukemia By Targeting Cellular Metabolism

Kanwaldeep Singh, Emily Hartung, Christina Muhs, Islam Alshamleh, Monisha Divakaran, Anna Dvorkin-Gheva, Sara Pishyar, Pradhariny Prabagaran, Dina Khalaf, Alejandro Garcia-Horton, Stephen Ronan Foley, Brian Leber, Irwin Walker, Kylie Lepic, Harald Schwalbe, Hubert Serve, Maria Kleppe, Hugh Young Rienhoff, Jr., Tobias Berg

Blood (2023) 142 (Supplement 1): 4156.

https://doi.org/10.1182/blood-2023-189515

Published: 2023

Journal Articles

Mimicking Clinical Trials with Synthetic Acute Myeloid Leukemia Patients Using Generative Artificial Intelligence

Jan-Niklas Eckardt, Waldemar Hahn, Christoph Röllig, Sebastian Stasik, Uwe Platzbecker, Carsten Müller-Tidow, Hubert Serve, Claudia D Baldus, Christoph Schliemann, Kerstin Schäfer-Eckart, Maher Hanoun, Martin Kaufmann, Andreas Burchert, Christian Thiede, Johannes Schetelig, Martin Bornhäuser, Markus Wolfien, Jan Moritz Middeke

Blood (2023) 142 (Supplement 1): 2268.

https://doi.org/10.1182/blood-2023-179817

Published: 2023

NARROW

Chemotherapy or Stem Cell Transplantation in Adult High Risk Ph/BCR::ABL1-Negative ALL Patients with Early MRD Negativity: Results of the Randomized GMALL Trial 08/2013

The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients

Characterizing the Microbiome-Immune Axis in Hematopoietic Stem Cell Recipients

Outcome of Patients with Hematologic or Molecular Relapsed/Refractory (R/R) Acute T- Lymphoblastic Leukemia - Data from the GMALL Study Group

10 Year Follow-up of CALGB 10603/Ratify: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years

Age-Stratified Game-Theory-Informed Machine Learning of Molecular Alterations Unveils Prognostic Divergence in 3062 Pediatric and Adult Acute Myeloid Leukemia Patients

Clonal Dynamics of Leukemic and Clonal Hematopoiesis Mutations Predict Relapse in Single Cell MRD Analysis of AML in First Complete Remission

HLA-DR Expression on Leukemic Progenitor Cells before Allogeneic Hematopoietic Cell Transplantation Adds Prognostic Value in the Presence of MRD

Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1 -Mutated AML - the SAL/AMLCG Vincent Trial

Follow-up of the Randomized ASAP Trial Shows No Survival Advantage for Patients with Poor Responsive or Relapsed AML Who Received Intensive Salvage Chemotherapy for Remission Induction Prior to Allogeneic Transplantation Compared to Immediate Allogeneic Transplantation

Update on GMALL Trial 08/2013 Shows Durable Favorable Outcome of Newly Diagnosed Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) with Imatinib, Dose-Reduced Induction Followed By Stem Cell Transplantation

Incidence, Risk Factors, and Outcomes of Candida Bloodstream Infections in Hematological and Oncological Patients

Epigenetic control over the cell-intrinsic immune response antagonizes self-renewal in acute myeloid leukemia

Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Patients with Ph/BCR::ABL Negative B-Precursor Adult Lymphoblastic Leukemia (ALL): Preliminary Results of the GMALL Bold Trial

Secondary-Type Mutations Do Not Impact the Favorable Outcome of NPM1 -Mutated Acute Myeloid Leukemia Patients - Results from a Large Cohort of Intensively Treated Patients

CNS Irradiation in Adult De Novo B-Precursor ALL / Lbl: Results of the Randomized GMALL T rial 08/2013 Indicate Potential Antileukemic Efficacy

Impact of KMT2A -PTD Mutational Subgroups on Outcome of AML Patients after Induction Therapy and Allogeneic Hematopoietic Cell Transplantation

Immune Responses after One Versus Two Influenza A/B Vaccinations in Patients with Multiple Myeloma

LSD1 Inhibition Synergizes with Venetoclax in Acute Myeloid Leukemia By Targeting Cellular Metabolism

Mimicking Clinical Trials with Synthetic Acute Myeloid Leukemia Patients Using Generative Artificial Intelligence

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only